A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma

A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma

Abstract Objective This study aimed to explore the efficacy and safety of combining epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with ZiLongJin Tablet (ZLJT) in delaying acquired resistance in advanced EGFR-mutant lung adenocarcinoma (LUAD) patients. Furthermore, we employ...

Full description

Bibliographic Details
Main Authors: Xue Han, Lan Liang, Chenming He, Qinyou Ren, Jialin Su, Liang Cao, Jin Zheng
Format: Article
Language:English
Published: BMC 2023-11-01
Series:BMC Complementary Medicine and Therapies
Subjects:
Lung adenocarcinoma
ZiLongJin Tablet
Epidermal growth factor receptor-tyrosine kinase inhibitor
Real-world study
Network pharmacology
Molecular docking simulation
Online Access:https://doi.org/10.1186/s12906-023-04213-3

Internet

https://doi.org/10.1186/s12906-023-04213-3

Similar Items